Back to top
more

Dynavax Technologies (DVAX)

(Real Time Quote from BATS)

$10.97 USD

10.97
856,499

-0.22 (-1.97%)

Updated Sep 11, 2024 01:40 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (82 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Novartis (NVS) Plans to Spin Off Generics Business Sandoz

by Zacks Equity Research

Novartis (NVS) is set to spin off Sandoz into a new publicly traded standalone company to focus better on its core pharmaceutical business.

Is Dynavax Technologies (DVAX) a Great Value Stock Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Foghorn (FHTX) Phase I AML/MDS Study on Full Clinical Hold

by Zacks Equity Research

Foghorn (FHTX) receives yet another setback as the phase I dose escalation study of FHD-286 in relapsed and/or refractory AML and MDS has been put on full clinical hold.

Aerie (AERI) to be Acquired by Alcon for $770M, Shares Up

by Zacks Equity Research

Aerie (AERI) enters into an agreement with Alcon to be acquired for $770 million. Shares gain.

Gilead (GILD) Twice-Yearly HIV Treatment Gets EC Approval

by Zacks Equity Research

Gilead (GILD) HIV treatment Sunlenca gets approved by the European Commission for adults with multi-drug resistant HIV infection for whom it is otherwise not possible to construct a suppressive anti-viral regimen.

Intercept (ICPT) Settles Litigation With Dr. Reddy's for Ocaliva

by Zacks Equity Research

Intercept (ICPT) enters into a settlement agreement with Dr. Reddy's for lead drug Ocaliva's generic version.

Endo (ENDP) Files for Bankruptcy Amid Litigations, Huge Debt

by Zacks Equity Research

Endo (ENDP) finally files for bankruptcy after negotiations with its debtholders as litigation claims continue to weigh on the business.

Gilead (GILD) Announces Positive Data on Breast Cancer Drug

by Zacks Equity Research

Gilead (GILD) breast cancer drug Trodelvy improves overall survival in pre-treated HR+/HER2- metastatic breast cancer patients. The company will also acquire the remaining rights to the drug.

Novartis (NVS) NSCLC Study Fails to Meet Primary Endpoint

by Zacks Equity Research

Novartis (NVS) suffers a setback as canakinumab fails to meet the primary goal in yet another study for lung cancer.

Roche (RHHBY) Influenza Drug Gets FDA Nod for Children

by Zacks Equity Research

Roche (RHHBY) obtains FDA approval for expanded indication of influenza drug Xofluza.

Bausch (BHC) Q2 Earnings & Sales Miss, View Cut, Stock Down

by Zacks Equity Research

Bausch (BHC) Q2 earnings and sales miss in the second quarter. The company cuts its annual guidance due to the uncertainties in the overall operating environment.

Viatris' (VTRS) Q2 Earnings Beat, Revenues Miss Estimates

by Zacks Equity Research

Viatris (VTRS) beats on Q2 earnings but misses sales estimates. The company is on track to close its biosimilars deal with Biocon Biologics in the second half.

How Much Upside is Left in Dynavax Technologies (DVAX)? Wall Street Analysts Think 92%

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 92.2% in Dynavax Technologies (DVAX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Dynavax Technologies (DVAX) Recently Broke Out Above the 20-Day Moving Average

by Zacks Equity Research

When a stock breaks out above the 20-day simple moving average, good things could be on the horizon. How should investors react?

Aerie (AERI) Q2 Loss Narrower Than Expected, Sales Beat

by Zacks Equity Research

Aerie (AERI) Q2 loss narrows year over year and revenues beat estimates in the second quarter of 2022.

bluebird (BLUE) Q2 Loss Narrower Than Expected, Sales Miss

by Zacks Equity Research

bluebird (BLUE) posts a narrower-than-expected loss in the second quarter. However, sales miss estimates.

Dynavax Technologies (DVAX) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Dynavax Technologies (DVAX) delivered earnings and revenue surprises of 290.91% and 73.80%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

FATE's Q2 Loss Narrower Than Expected, Pipeline in Focus

by Zacks Equity Research

FATE reports a narrower loss and higher collaboration revenues in the second quarter.

Is Axonics (AXNX) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Axonics Modulation Technologies (AXNX) and Dynavax Technologies (DVAX) have performed compared to their sector so far this year.

Gilead (GILD) Q2 Earnings & Sales Top, Revenue Outlook Upped

by Zacks Equity Research

Gilead (GILD) reports better-than-expected second quarter results on strong HIV business. The company also raises its annual revenue guidance.

Wall Street Analysts See an 111% Upside in Dynavax Technologies (DVAX): Can the Stock Really Move This High?

by Zacks Equity Research

The mean of analysts' price targets for Dynavax Technologies (DVAX) points to an 111.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Exact Sciences (EXAS) Surges 6.9%: Is This an Indication of Further Gains?

by Zacks Equity Research

Exact Sciences (EXAS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Myovant Sciences (MYOV) Moves 7.7% Higher: Will This Strength Last?

by Zacks Equity Research

Myovant Sciences (MYOV) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Dynavax (DVAX) Up as EMA Accepts Valneva's COVID-19 Vaccine MAA

by Zacks Equity Research

Dynavax (DVAX) gains as the EMA accepts partner Valneva's MAA for COVID-19 vaccine.

Dynavax Technologies (DVAX) Misses Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Dynavax Technologies (DVAX) delivered earnings and revenue surprises of -8.33% and 3.20%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?